Učitavanje...
RTL THERAPY FOR MULTIPLE SCLEROSIS: A Phase I Clinical Study
A human Recombinant T-cell receptor Ligand (RTL1000) consisting of DR2 α1 and β1 domains linked covalently to MOG-35-55 peptide can reverse clinical and histological signs of experimental autoimmune encephalomyelitis (EAE), and was evaluated for safety in a Phase 1 randomized, placebo-controlled, es...
Spremljeno u:
| Glavni autori: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2010
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3026883/ https://ncbi.nlm.nih.gov/pubmed/20965577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jneuroim.2010.09.013 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|